Project Grant R21CA303409

Award Date 6/10/25
Completion Date 5/31/27
Dollars Obligated $435K
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, spanning June 2025 to May 2030, supports research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying inhibitors of the chromatin reader SGF29 as a potential novel therapeutic approach for acute myeloid leukemia (AML). The project will implement high-throughput screening assays developed by the researchers to screen chemical compound libraries and identify selective SGF29...
This $456,500 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) federal grant program supports research to identify and characterize the Drosophila NSE5/6 protein complex. The overarching goal is to illuminate the mechanisms of heterochromatin repair, a critical process for maintaining genome stability. Key objectives include determining the structure and functions of the NSE5/6 complex in Drosophila, a model...
This $394,482 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate demineralized bone paper (DBP)-based human bone metabolic and senolytic assays to support bone-targeting drug discovery and treatment regimens. The proposed DBP-based models will provide predictive bone assays for screening new anti-bone-aging drugs and improving treatment strategies for cancer survivors at risk of...
This federal Project Grant award of $531,379, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The primary goals of this 5-year study are to: 1) Investigate baseline mitochondrial network architecture as a critical factor influencing NSCLC response to ADCs with the DXD...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the Sloan-Kettering Institute for Cancer Research to investigate mechanisms through which deficiency of the SMARCA4 gene promotes metastasis in lung adenocarcinoma. The research aims to elucidate the role of the ROR2/p-GSK3bS9 signaling pathway in driving metastasis in SMARCA4-deficient lung cancer. Key activities include conducting RNA-seq, ChIP-seq, ATAC-seq, and mass...
This $491,357 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at Case Western Reserve University to investigate a novel approach for treating acute myeloid leukemia (AML). The key objectives are to study the mechanisms by which a small molecule that activates the mTORC1 signaling pathway can sensitize AML cells to proteasome inhibitor drugs, leading to mitochondrial damage and reversal of drug resistance. The researchers...
This National Cancer Institute (NCI) Project Grant award under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program provides $408,913 to the University of California Irvine from August 15, 2024 to July 31, 2029. The project investigates the mechanisms by which genes encoding ribosomal proteins are used as sensors for altered cellular chromosome content in fruit flies, a genetic model system. The research aims to define the molecular basis for cellular recognition and...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
The National Institutes of Health (NIH) awarded a $239,363 Project Grant under the Research Infrastructure Programs (CFDA 93.351) to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. The grant aims to determine the radioprotective efficacy of dietary administration of highly radiation-resistant non-pathogenic fungi in the Drosophila model system. The research will evaluate if consumption of these fungal strains can increase resistance to acute radiation damage across...

The National Cancer Institute (NCI) has awarded a $434,542 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Icahn School of Medicine at Mount Sinai to develop a Drosophila (fruit fly) model to study the genetic susceptibility to adverse side effects, such as musculoskeletal pain, caused by aromatase inhibitor (AI) cancer drugs like letrozole, anastrozole, and exemestane. This 2-year project aims to use unbiased genetic screens and compound screens in the fly model to identify candidate therapeutics and genetic variants that contribute to AI toxicity. The goal is to match breast cancer patients with the specific AI they are most likely to tolerate from the outset, eliminating the need for a painful trial-and-error process of switching between AIs. The project leverages the rich set of Drosophila assays and tools to dissect the genetic basis of AI-induced side effects, with plans to validate the findings in mammalian models and patient datasets in the future.

Generated 7/1/25, 2:42 AM